Herpes Zoster Incidence Differs Among Janus Kinase Inhibitors, While Permanent Discontinuation Rates Remain Comparable

This publication has 12 references indexed in Scilit:

• Impaired cellular immune responses to herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
  Rheumatology, 2025
• Differences in immunogenicity to zoster recombinant vaccine in IMID patients undergoing treatment with non-selective or selective JAK-i
  Rheumatology, 2025
• Immunogenicity to herpes zoster recombinant subunit vaccine in immune-mediated rheumatic patients under treatment with JAK inhibitors
  Rheumatology, 2024
• Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea
  Seminars in Arthritis and Rheumatism, 2024
• Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors
  Rheumatology, 2023
• 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
  Arthritis Care & Research, 2023
• Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity
  Rheumatology, 2022
• Contribution of a European‐Prevalent Variant near CD83 and an East Asian–Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome‐Wide Association Study Meta‐Analyses
  Arthritis & Rheumatology, 2021
• JAK inhibitors and infections risk: focus on herpes zoster
  Therapeutic Advances in Musculoskeletal Disease, 2020
• Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
  Bone Marrow Transplantation, 2012